

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Turley, et al.

Group Art Unit: 1615

Application No.: 09/685,010

Examiner: Unassigned

Filed: October 5, 2000

For: Compositions and Methods for Treating Cellular Response to Injury and Other Proliferating Cell Disorders Regulated by Hyaladherin and Hyaluronans

CERTIFICATE OF FIRST CLASS MAILING
OF INFORMATION DISCLOSURE STATEMENT

I HEREBY CERTIFY THAT THIS CORRESPONDENCE (Information Disclosure Statement, IDS form 1449, 10 references, transmittal letter and return postcard) IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C., 20231, ON November 5, 2001:

Date: November 5, 2001

By: Bridgette E. Massey
Bridgette E. Massey



Patent
Attorney's Docket No. 033352-007

TECH CENTER 1600/2900

DEC 10 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Turley, et al.

Application No.: 09/685,010

Filed: October 5, 2000

For: Compositions and Methods for Treating
Cellular Response to Injury and Other
Proliferating Cell Disorders Regulated by
Hyaladherin and Hyaluronans

Group Art Unit: 1615

Examiner: Unassigned

**INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$ _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$ _____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650) 622-2300

By: Mary Ann Dillahunt
Mary Ann Dillahunt
Registration No. 34,576

Date: October 30, 2001



RECEIVED

DEC 10 2001

TECH CENTER 1600/2900

Attorney's Docket No. 033352-007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
)
Turley, et al.) Group Art Unit: 1615
)
Application No.: 09/685,010) Examiner: Unassigned
)
Filed: October 5, 2000)
)
For: Compositions and Methods for Treating)
Cellular Response to Injury and Other)
Proliferating Cell Disorders Regulated by)
Hyaladherin and Hyaluronans)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited below is enclosed:

Foreign Patents/Applications

International Search Report dated 8/22/2001 in co-pending PCT Application No. PCT/IB00/01534

WO 93/21312	Pub. Date: 10/28/93
WO 00/01841	Pub. Date: 1/13/00
WO 00/29447	Pub. Date: 5/25/00
EP 0 721 012	Pub. Date: 7/10/96
EP 0 950 708	Pub. Date: 10/20/99



Articles

Chao, et al., "The characterization of a human RHAMM cDNA: conservation of they hyaluronan-binding domains", *Gene*, Vol. 174, No. 2, (1996), pp. 299-306.


Jean, et al., "Unmasking a Hyaluronan-binding site of the BX7B type in the H3 heavy chain of the inter-alpha-inhibitor family", *European Journal of Biochemistry*, Vol. 268, No. 3, (1 Feb. 2001), pp. 544-553.

Volker, et al., " The human hyaluron receptor RHAMM is expressed as an intracellular protein in breast cancer cells", *J. Cell Science*, Vol. 111, (1998), pp. 1685-1694.

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee is required under 37 C.F.R. § 1.97(b).

I, the undersigned, hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. Please note that reference WO 97/38098, which was also cited in the International Search Report for PCT application no. PCT/IB00/01534, was previously submitted in this application in the IDS filed on February 26, 2001.

The Examiner's attention is directed to copending application number 09/541,522 naming Eva A. Turley, Tony F. Cruz, and A. Robin Poole as inventor(s) and filed on April 3, 2000, and the documents cited therein, a copy of which is enclosed.

 In accordance with MPEP § 609(c)(2) (February 2000, page 600-107), the Office is requested to return a copy of this Information Disclosure Statement with the Examiner's initials adjacent to this paragraph indicating that this copending application has been considered. By citation to the copending application, confidentiality is not waived and the Office is requested to maintain the confidentiality of the copending application under 35 U.S.C. § 122.

To assist the Examiner, the documents listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: Mary Ann Dillahunty
Mary Ann Dillahunty
Registration No. 34,576

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650) 622-2300

Date: October 30, 2001